HOME >> BIOLOGY >> NEWS
New Military Biomaterials R&D Center to hold first meeting

NEW BRUNSWICK/PISCATAWAY The new Center for Military Biomaterials Research (CeMBR) has been set up by the New Jersey Center for Biomaterials. The CeMBR will hold its first open meeting on Oct. 20, 2004 at 10 a.m. in the Hyatt Regency, Two Albany Street, New Brunswick, N.J.

The inaugural meeting agenda will include a summary of the science and technology roadmap created by the National Research Council to guide the Center, and discussion of potential R&D projects for the program's second year.

The CeBMR was established through the award of an initial $827,000 contract from the U.S. Army Medical Research and Materiel Command. The award is renewable for at least two years with increasing funding already provided by Congress to enable expansion of the program. This initiative will provide rapid and effective pathways for identification, development and utilization of biomaterial-based technologies and products for the military's most urgent healthcare needs on and off the battlefield.

One of the first technology platforms the CeBMR is supporting is a sprayable wound dressing designed to enable soldiers to treat their own small gunshot wounds, burns, abrasions or cuts, so that they may complete a three-day mission and rapidly return to duty. The sprayable dressing technology will then be expanded to provide pain relief, mitigate bleeding and reduce infection. Biocure, Inc. of Norcross, Ga., is developing this technology.

The CeBMR is unique among organizations active in the field because of its network of academic, military and industry leaders working to speed the introduction of biomaterial products to meet the military's requirements. This center is pursuing a "market focused" strategy of applied research, product development and commercialization of prototype products leveraged from industry and academia. When there are no existing enabling technologies that meet the military's requirements, the CeBMR will form research partne
'"/>

Contact: David Devore
devore@rutchem.rutgers.edu
732-445-0488
Rutgers, the State University of New Jersey
6-Oct-2004


Page: 1 2

Related biology news :

1. Military to study better pain relief in battle zones
2. Military bases can benefit by addressing sprawl issues and biodiversity
3. Military hazards are greater for Native Americans, according to sociological research
4. Sukhishvili invited to serve on NIHs Biomaterials and Biointerfaces Study Section
5. Psychiatric Genomics Center established at Cold Spring Harbor Laboratory
6. Energy department selects 3 Bioenergy Research Centers for $375 million in federal funding
7. Woods Hole Research Center scientists study impacts of industrial logging in Central Africa
8. Innovative smallpox vaccine research study to be conducted at Case Medical Center
9. CSHL selected for odENCODE Data Coordination Center
10. Woods Hole Research Center scientists using remote sensing tools to predict bird species richness
11. NYUs Center for Comparative Functional Genomics part of $57 million MOD-ENCODE consortium

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Military Biomaterials Center hold first meeting

(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: